Medical Care
Global Immuno-Oncology Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
- Jun 28, 25
- ID: 341166
- Pages: 123
- Figures: 129
- Views: 6
In 2024, the global market size of Immuno-Oncology was estimated to be worth US$ 57510 million and is forecast to reach approximately US$ 150070 million by 2031 with a CAGR of 14.9% during the forecast period 2025-2031.
Immuno-Oncology (I-O) is an innovative area of research that seeks to help the body"s own immune system fight cancer. The goal is to address the unmet need for long-term survival in patients with advanced cancers.
The industry"s leading producers are Bristol-Myers Squibb, Merck & Co and Roche AG, with revenues of 27.89%, 22.10% and 20.85%, respectively, in 2019.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Immuno-Oncology, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Immuno-Oncology.
The Immuno-Oncology market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Immuno-Oncology market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Immuno-Oncology companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Market Segmentation
By Company
Bristol-Myers Squibb
Merck & Co., Inc.
Roche AG
AstraZeneca, Plc
Sanofi S.A.
Dendreon Pharmaceuticals
Novartis
Gilead Sciences Inc.
Merck KGaA
Segment by Type
Immune Checkpoint Inhibitors
Cytokine-Based Immunotherapy
Cancer Vaccines
CAR-T Cell Therapy
Others
Segment by Application
Hospitals
Drugstores
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
Chapter 2: Revenue of Immuno-Oncology in global and regional level.
Chapter 3: Detailed analysis of Immuno-Oncology company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Immuno-Oncology revenue, gross margin, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 8: Europe by Type, by Application and by country, revenue for each segment.
Chapter 9: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion
Immuno-Oncology (I-O) is an innovative area of research that seeks to help the body"s own immune system fight cancer. The goal is to address the unmet need for long-term survival in patients with advanced cancers.
The industry"s leading producers are Bristol-Myers Squibb, Merck & Co and Roche AG, with revenues of 27.89%, 22.10% and 20.85%, respectively, in 2019.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Immuno-Oncology, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Immuno-Oncology.
The Immuno-Oncology market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Immuno-Oncology market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Immuno-Oncology companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Market Segmentation
By Company
Bristol-Myers Squibb
Merck & Co., Inc.
Roche AG
AstraZeneca, Plc
Sanofi S.A.
Dendreon Pharmaceuticals
Novartis
Gilead Sciences Inc.
Merck KGaA
Segment by Type
Immune Checkpoint Inhibitors
Cytokine-Based Immunotherapy
Cancer Vaccines
CAR-T Cell Therapy
Others
Segment by Application
Hospitals
Drugstores
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
Chapter 2: Revenue of Immuno-Oncology in global and regional level.
Chapter 3: Detailed analysis of Immuno-Oncology company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Immuno-Oncology revenue, gross margin, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 8: Europe by Type, by Application and by country, revenue for each segment.
Chapter 9: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion
1 Study Coverage
1.1 Immuno-Oncology Product Introduction
1.2 Market by Type
1.2.1 Global Immuno-Oncology Market Size Growth Rate by Type (2020 VS 2024 VS 2031)
1.2.2 Immune Checkpoint Inhibitors
1.2.3 Cytokine-Based Immunotherapy
1.2.4 Cancer Vaccines
1.2.5 CAR-T Cell Therapy
1.2.6 Others
1.3 Market by Application
1.3.1 Global Immuno-Oncology Market Size Growth Rate by Application (2020 VS 2024 VS 2031)
1.3.2 Hospitals
1.3.3 Drugstores
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Immuno-Oncology Market Size Estimates and Forecasts
2.2 Immuno-Oncology Market Size by Region: 2024 Versus 2031
2.2.1 Global Immuno-Oncology Revenue by Region: 2020-2025
2.2.2 Global Immuno-Oncology Revenue Forecast by Region (2026-2031)
2.2.3 Global Immuno-Oncology Revenue Market Share by Region (2020-2031)
3 Market Segments
3.1 Breakdown Data by Type
3.1.1 Global Immuno-Oncology Revenue by Type (2020-2031)
3.1.2 Global Immuno-Oncology Revenue Market Share by Type (2020-2031)
3.2 Breakdown Data by Application
3.2.1 Global Immuno-Oncology Revenue by Application (2020-2031)
3.2.2 Global Immuno-Oncology Revenue Market Share by Application (2020-2031)
3.3 by Type and by Application Crossing Analysis
3.3.1 Immune Checkpoint Inhibitors of Immuno-Oncology Revenue Market Share by Application
3.3.2 Cytokine-Based Immunotherapy of Immuno-Oncology Revenue Market Share by Application
3.3.3 Cancer Vaccines of Immuno-Oncology Revenue Market Share by Application
3.3.4 CAR-T Cell Therapy of Immuno-Oncology Revenue Market Share by Application
3.3.5 Others of Immuno-Oncology Revenue Market Share by Application
4 Global Immuno-Oncology by Company
4.1 Global Immuno-Oncology Revenue by Company (2020-2025)
4.2 Global Immuno-Oncology Revenue Share by Company (2020-2025)
4.3 Competitive Landscape
4.3.1 Key Immuno-Oncology Companies around the World: Ranking by Revenue
4.3.2 Global Immuno-Oncology Market Concentration Ratio (CR5 and HHI) & (2020-2025)
4.3.3 Global Immuno-Oncology Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.4 Global Immuno-Oncology Companies Headquarters & Product Type
4.4.1 Global Immuno-Oncology Companies Headquarters
4.4.2 Date of International Companies Enter into Immuno-Oncology Market
4.4.3 Global Immuno-Oncology Companies Product & Service
4.4.4 Immune Checkpoint Inhibitors Revenue Market Share of Immuno-Oncology by Company
4.4.5 Cytokine-Based Immunotherapy Revenue Market Share of Immuno-Oncology by Company
4.4.6 Cancer Vaccines Revenue Market Share of Immuno-Oncology by Company
4.4.7 CAR-T Cell Therapy Revenue Market Share of Immuno-Oncology by Company
4.4.8 Others Revenue Market Share of Immuno-Oncology by Company
4.5 Global Immuno-Oncology Mergers & Acquisitions, Expansion Plans
5 Company Profiles
5.1 Bristol-Myers Squibb
5.1.1 Bristol-Myers Squibb Corporation Information
5.1.2 Bristol-Myers Squibb Description, Business Overview
5.1.3 Bristol-Myers Squibb Immuno-Oncology Products Offered
5.1.4 Bristol-Myers Squibb Immuno-Oncology Revenue and Gross Margin (2020-2025)
5.1.5 Bristol-Myers Squibb Immuno-Oncology Revenue by Product in 2024
5.1.6 Bristol-Myers Squibb Immuno-Oncology Revenue by Application in 2024
5.1.7 Bristol-Myers Squibb Immuno-Oncology Revenue by Geographic Area in 2024
5.1.8 Bristol-Myers Squibb Recent Developments
5.2 Merck & Co., Inc.
5.2.1 Merck & Co., Inc. Corporation Information
5.2.2 Merck & Co., Inc. Description, Business Overview
5.2.3 Merck & Co., Inc. Immuno-Oncology Products Offered
5.2.4 Merck & Co., Inc. Immuno-Oncology Revenue and Gross Margin (2020-2025)
5.2.5 Merck & Co., Inc. Immuno-Oncology Revenue by Product in 2024
5.2.6 Merck & Co., Inc. Immuno-Oncology Revenue by Application in 2024
5.2.7 Merck & Co., Inc. Immuno-Oncology Revenue by Geographic Area in 2024
5.2.8 Merck & Co., Inc. Recent Developments
5.3 Roche AG
5.3.1 Roche AG Corporation Information
5.3.2 Roche AG Description, Business Overview
5.3.3 Roche AG Immuno-Oncology Products Offered
5.3.4 Roche AG Immuno-Oncology Revenue and Gross Margin (2020-2025)
5.3.5 Roche AG Immuno-Oncology Revenue by Product in 2024
5.3.6 Roche AG Immuno-Oncology Revenue by Application in 2024
5.3.7 Roche AG Immuno-Oncology Revenue by Geographic Area in 2024
5.3.8 Roche AG Recent Developments
5.4 AstraZeneca, Plc
5.4.1 AstraZeneca, Plc Corporation Information
5.4.2 AstraZeneca, Plc Description, Business Overview
5.4.3 AstraZeneca, Plc Immuno-Oncology Products Offered
5.4.4 AstraZeneca, Plc Immuno-Oncology Revenue and Gross Margin (2020-2025)
5.4.5 AstraZeneca, Plc Immuno-Oncology Revenue by Product in 2024
5.4.6 AstraZeneca, Plc Immuno-Oncology Revenue by Application in 2024
5.4.7 AstraZeneca, Plc Immuno-Oncology Revenue by Geographic Area in 2024
5.4.8 AstraZeneca, Plc Recent Developments
5.5 Sanofi S.A.
5.5.1 Sanofi S.A. Corporation Information
5.5.2 Sanofi S.A. Description, Business Overview
5.5.3 Sanofi S.A. Immuno-Oncology Products Offered
5.5.4 Sanofi S.A. Immuno-Oncology Revenue and Gross Margin (2020-2025)
5.5.5 Sanofi S.A. Immuno-Oncology Revenue by Product in 2024
5.5.6 Sanofi S.A. Immuno-Oncology Revenue by Application in 2024
5.5.7 Sanofi S.A. Immuno-Oncology Revenue by Geographic Area in 2024
5.5.8 Sanofi S.A. Recent Developments
5.6 Dendreon Pharmaceuticals
5.6.1 Dendreon Pharmaceuticals Corporation Information
5.6.2 Dendreon Pharmaceuticals Description, Business Overview
5.6.3 Dendreon Pharmaceuticals Immuno-Oncology Products Offered
5.6.4 Dendreon Pharmaceuticals Immuno-Oncology Revenue and Gross Margin (2020-2025)
5.6.5 Dendreon Pharmaceuticals Immuno-Oncology Revenue by Product in 2024
5.6.6 Dendreon Pharmaceuticals Immuno-Oncology Revenue by Application in 2024
5.6.7 Dendreon Pharmaceuticals Immuno-Oncology Revenue by Geographic Area in 2024
5.6.8 Dendreon Pharmaceuticals Recent Developments
5.7 Novartis
5.7.1 Novartis Corporation Information
5.7.2 Novartis Description, Business Overview
5.7.3 Novartis Immuno-Oncology Products Offered
5.7.4 Novartis Immuno-Oncology Revenue and Gross Margin (2020-2025)
5.7.5 Novartis Immuno-Oncology Revenue by Product in 2024
5.7.6 Novartis Immuno-Oncology Revenue by Application in 2024
5.7.7 Novartis Immuno-Oncology Revenue by Geographic Area in 2024
5.7.8 Novartis Recent Developments
5.8 Gilead Sciences Inc.
5.8.1 Gilead Sciences Inc. Corporation Information
5.8.2 Gilead Sciences Inc. Description, Business Overview
5.8.3 Gilead Sciences Inc. Immuno-Oncology Products Offered
5.8.4 Gilead Sciences Inc. Immuno-Oncology Revenue and Gross Margin (2020-2025)
5.8.5 Gilead Sciences Inc. Immuno-Oncology Revenue by Product in 2024
5.8.6 Gilead Sciences Inc. Immuno-Oncology Revenue by Application in 2024
5.8.7 Gilead Sciences Inc. Immuno-Oncology Revenue by Geographic Area in 2024
5.8.8 Gilead Sciences Inc. Recent Developments
5.9 Merck KGaA
5.9.1 Merck KGaA Corporation Information
5.9.2 Merck KGaA Description, Business Overview
5.9.3 Merck KGaA Immuno-Oncology Products Offered
5.9.4 Merck KGaA Immuno-Oncology Revenue and Gross Margin (2020-2025)
5.9.5 Merck KGaA Immuno-Oncology Revenue by Product in 2024
5.9.6 Merck KGaA Immuno-Oncology Revenue by Application in 2024
5.9.7 Merck KGaA Immuno-Oncology Revenue by Geographic Area in 2024
5.9.8 Merck KGaA Recent Developments
6 North America
6.1 North America Immuno-Oncology Market Size YoY Growth 2020-2031
6.2 North America Immuno-Oncology Market Facts & Figures by Country (2020-2031)
6.3 North America Immuno-Oncology Revenue by Type (2020-2025)
6.4 North America Immuno-Oncology Revenue by Application (2020-2025)
7 Asia-Pacific
7.1 Asia-Pacific Immuno-Oncology Market Size YoY Growth 2020-2031
7.2 Asia-Pacific Immuno-Oncology Market Facts & Figures by Region (2020-2031)
7.3 Asia-Pacific Immuno-Oncology Revenue by Type (2020-2025)
7.4 Asia-Pacific Immuno-Oncology Revenue by Application (2020-2025)
8 Europe
8.1 Europe Immuno-Oncology Market Size YoY Growth 2020-2031
8.2 Europe Immuno-Oncology Market Facts & Figures by Country (2020-2031)
8.3 Europe Immuno-Oncology Revenue by Type (2020-2025)
8.4 Europe Immuno-Oncology Revenue by Application (2020-2025)
9 Latin America
9.1 Latin America Immuno-Oncology Market Size YoY Growth 2020-2031
9.2 Latin America Immuno-Oncology Market Facts & Figures by Country (2020-2031)
9.3 Latin America Immuno-Oncology Revenue by Type (2020-2025)
9.4 Latin America Immuno-Oncology Revenue by Application (2020-2025)
10 Middle East and Africa
10.1 Latin America Immuno-Oncology Market Size YoY Growth 2020-2031
10.2 Middle East and Africa Immuno-Oncology Market Facts & Figures by Country (2020-2031)
10.3 Middle East and Africa Immuno-Oncology Revenue by Type (2020-2025)
10.4 Middle East and Africa Immuno-Oncology Revenue by Application (2020-2025)
11 Supply Chain and Sales Channel analysis
11.1 Immuno-Oncology Supply Chain Analysis
11.2 Immuno-Oncology Key Raw Materials and Upstream Suppliers
11.3 Immuno-Oncology Clients Analysis
11.4 Immuno-Oncology Sales Channel and Sales Model Analysis
11.4.1 Immuno-Oncology Distribution Channel Analysis: Indirect Sales VS Direct Sales
11.4.2 Immuno-Oncology Distribution Channel Analysis: Online Sales VS Offline Sales
11.4.3 Immuno-Oncology Distributors
12 Immuno-Oncology Market Dynamics
12.1 Immuno-Oncology Industry Trends
12.2 Immuno-Oncology Market Drivers
12.3 Immuno-Oncology Market Challenges
12.4 Immuno-Oncology Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
1.1 Immuno-Oncology Product Introduction
1.2 Market by Type
1.2.1 Global Immuno-Oncology Market Size Growth Rate by Type (2020 VS 2024 VS 2031)
1.2.2 Immune Checkpoint Inhibitors
1.2.3 Cytokine-Based Immunotherapy
1.2.4 Cancer Vaccines
1.2.5 CAR-T Cell Therapy
1.2.6 Others
1.3 Market by Application
1.3.1 Global Immuno-Oncology Market Size Growth Rate by Application (2020 VS 2024 VS 2031)
1.3.2 Hospitals
1.3.3 Drugstores
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Immuno-Oncology Market Size Estimates and Forecasts
2.2 Immuno-Oncology Market Size by Region: 2024 Versus 2031
2.2.1 Global Immuno-Oncology Revenue by Region: 2020-2025
2.2.2 Global Immuno-Oncology Revenue Forecast by Region (2026-2031)
2.2.3 Global Immuno-Oncology Revenue Market Share by Region (2020-2031)
3 Market Segments
3.1 Breakdown Data by Type
3.1.1 Global Immuno-Oncology Revenue by Type (2020-2031)
3.1.2 Global Immuno-Oncology Revenue Market Share by Type (2020-2031)
3.2 Breakdown Data by Application
3.2.1 Global Immuno-Oncology Revenue by Application (2020-2031)
3.2.2 Global Immuno-Oncology Revenue Market Share by Application (2020-2031)
3.3 by Type and by Application Crossing Analysis
3.3.1 Immune Checkpoint Inhibitors of Immuno-Oncology Revenue Market Share by Application
3.3.2 Cytokine-Based Immunotherapy of Immuno-Oncology Revenue Market Share by Application
3.3.3 Cancer Vaccines of Immuno-Oncology Revenue Market Share by Application
3.3.4 CAR-T Cell Therapy of Immuno-Oncology Revenue Market Share by Application
3.3.5 Others of Immuno-Oncology Revenue Market Share by Application
4 Global Immuno-Oncology by Company
4.1 Global Immuno-Oncology Revenue by Company (2020-2025)
4.2 Global Immuno-Oncology Revenue Share by Company (2020-2025)
4.3 Competitive Landscape
4.3.1 Key Immuno-Oncology Companies around the World: Ranking by Revenue
4.3.2 Global Immuno-Oncology Market Concentration Ratio (CR5 and HHI) & (2020-2025)
4.3.3 Global Immuno-Oncology Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.4 Global Immuno-Oncology Companies Headquarters & Product Type
4.4.1 Global Immuno-Oncology Companies Headquarters
4.4.2 Date of International Companies Enter into Immuno-Oncology Market
4.4.3 Global Immuno-Oncology Companies Product & Service
4.4.4 Immune Checkpoint Inhibitors Revenue Market Share of Immuno-Oncology by Company
4.4.5 Cytokine-Based Immunotherapy Revenue Market Share of Immuno-Oncology by Company
4.4.6 Cancer Vaccines Revenue Market Share of Immuno-Oncology by Company
4.4.7 CAR-T Cell Therapy Revenue Market Share of Immuno-Oncology by Company
4.4.8 Others Revenue Market Share of Immuno-Oncology by Company
4.5 Global Immuno-Oncology Mergers & Acquisitions, Expansion Plans
5 Company Profiles
5.1 Bristol-Myers Squibb
5.1.1 Bristol-Myers Squibb Corporation Information
5.1.2 Bristol-Myers Squibb Description, Business Overview
5.1.3 Bristol-Myers Squibb Immuno-Oncology Products Offered
5.1.4 Bristol-Myers Squibb Immuno-Oncology Revenue and Gross Margin (2020-2025)
5.1.5 Bristol-Myers Squibb Immuno-Oncology Revenue by Product in 2024
5.1.6 Bristol-Myers Squibb Immuno-Oncology Revenue by Application in 2024
5.1.7 Bristol-Myers Squibb Immuno-Oncology Revenue by Geographic Area in 2024
5.1.8 Bristol-Myers Squibb Recent Developments
5.2 Merck & Co., Inc.
5.2.1 Merck & Co., Inc. Corporation Information
5.2.2 Merck & Co., Inc. Description, Business Overview
5.2.3 Merck & Co., Inc. Immuno-Oncology Products Offered
5.2.4 Merck & Co., Inc. Immuno-Oncology Revenue and Gross Margin (2020-2025)
5.2.5 Merck & Co., Inc. Immuno-Oncology Revenue by Product in 2024
5.2.6 Merck & Co., Inc. Immuno-Oncology Revenue by Application in 2024
5.2.7 Merck & Co., Inc. Immuno-Oncology Revenue by Geographic Area in 2024
5.2.8 Merck & Co., Inc. Recent Developments
5.3 Roche AG
5.3.1 Roche AG Corporation Information
5.3.2 Roche AG Description, Business Overview
5.3.3 Roche AG Immuno-Oncology Products Offered
5.3.4 Roche AG Immuno-Oncology Revenue and Gross Margin (2020-2025)
5.3.5 Roche AG Immuno-Oncology Revenue by Product in 2024
5.3.6 Roche AG Immuno-Oncology Revenue by Application in 2024
5.3.7 Roche AG Immuno-Oncology Revenue by Geographic Area in 2024
5.3.8 Roche AG Recent Developments
5.4 AstraZeneca, Plc
5.4.1 AstraZeneca, Plc Corporation Information
5.4.2 AstraZeneca, Plc Description, Business Overview
5.4.3 AstraZeneca, Plc Immuno-Oncology Products Offered
5.4.4 AstraZeneca, Plc Immuno-Oncology Revenue and Gross Margin (2020-2025)
5.4.5 AstraZeneca, Plc Immuno-Oncology Revenue by Product in 2024
5.4.6 AstraZeneca, Plc Immuno-Oncology Revenue by Application in 2024
5.4.7 AstraZeneca, Plc Immuno-Oncology Revenue by Geographic Area in 2024
5.4.8 AstraZeneca, Plc Recent Developments
5.5 Sanofi S.A.
5.5.1 Sanofi S.A. Corporation Information
5.5.2 Sanofi S.A. Description, Business Overview
5.5.3 Sanofi S.A. Immuno-Oncology Products Offered
5.5.4 Sanofi S.A. Immuno-Oncology Revenue and Gross Margin (2020-2025)
5.5.5 Sanofi S.A. Immuno-Oncology Revenue by Product in 2024
5.5.6 Sanofi S.A. Immuno-Oncology Revenue by Application in 2024
5.5.7 Sanofi S.A. Immuno-Oncology Revenue by Geographic Area in 2024
5.5.8 Sanofi S.A. Recent Developments
5.6 Dendreon Pharmaceuticals
5.6.1 Dendreon Pharmaceuticals Corporation Information
5.6.2 Dendreon Pharmaceuticals Description, Business Overview
5.6.3 Dendreon Pharmaceuticals Immuno-Oncology Products Offered
5.6.4 Dendreon Pharmaceuticals Immuno-Oncology Revenue and Gross Margin (2020-2025)
5.6.5 Dendreon Pharmaceuticals Immuno-Oncology Revenue by Product in 2024
5.6.6 Dendreon Pharmaceuticals Immuno-Oncology Revenue by Application in 2024
5.6.7 Dendreon Pharmaceuticals Immuno-Oncology Revenue by Geographic Area in 2024
5.6.8 Dendreon Pharmaceuticals Recent Developments
5.7 Novartis
5.7.1 Novartis Corporation Information
5.7.2 Novartis Description, Business Overview
5.7.3 Novartis Immuno-Oncology Products Offered
5.7.4 Novartis Immuno-Oncology Revenue and Gross Margin (2020-2025)
5.7.5 Novartis Immuno-Oncology Revenue by Product in 2024
5.7.6 Novartis Immuno-Oncology Revenue by Application in 2024
5.7.7 Novartis Immuno-Oncology Revenue by Geographic Area in 2024
5.7.8 Novartis Recent Developments
5.8 Gilead Sciences Inc.
5.8.1 Gilead Sciences Inc. Corporation Information
5.8.2 Gilead Sciences Inc. Description, Business Overview
5.8.3 Gilead Sciences Inc. Immuno-Oncology Products Offered
5.8.4 Gilead Sciences Inc. Immuno-Oncology Revenue and Gross Margin (2020-2025)
5.8.5 Gilead Sciences Inc. Immuno-Oncology Revenue by Product in 2024
5.8.6 Gilead Sciences Inc. Immuno-Oncology Revenue by Application in 2024
5.8.7 Gilead Sciences Inc. Immuno-Oncology Revenue by Geographic Area in 2024
5.8.8 Gilead Sciences Inc. Recent Developments
5.9 Merck KGaA
5.9.1 Merck KGaA Corporation Information
5.9.2 Merck KGaA Description, Business Overview
5.9.3 Merck KGaA Immuno-Oncology Products Offered
5.9.4 Merck KGaA Immuno-Oncology Revenue and Gross Margin (2020-2025)
5.9.5 Merck KGaA Immuno-Oncology Revenue by Product in 2024
5.9.6 Merck KGaA Immuno-Oncology Revenue by Application in 2024
5.9.7 Merck KGaA Immuno-Oncology Revenue by Geographic Area in 2024
5.9.8 Merck KGaA Recent Developments
6 North America
6.1 North America Immuno-Oncology Market Size YoY Growth 2020-2031
6.2 North America Immuno-Oncology Market Facts & Figures by Country (2020-2031)
6.3 North America Immuno-Oncology Revenue by Type (2020-2025)
6.4 North America Immuno-Oncology Revenue by Application (2020-2025)
7 Asia-Pacific
7.1 Asia-Pacific Immuno-Oncology Market Size YoY Growth 2020-2031
7.2 Asia-Pacific Immuno-Oncology Market Facts & Figures by Region (2020-2031)
7.3 Asia-Pacific Immuno-Oncology Revenue by Type (2020-2025)
7.4 Asia-Pacific Immuno-Oncology Revenue by Application (2020-2025)
8 Europe
8.1 Europe Immuno-Oncology Market Size YoY Growth 2020-2031
8.2 Europe Immuno-Oncology Market Facts & Figures by Country (2020-2031)
8.3 Europe Immuno-Oncology Revenue by Type (2020-2025)
8.4 Europe Immuno-Oncology Revenue by Application (2020-2025)
9 Latin America
9.1 Latin America Immuno-Oncology Market Size YoY Growth 2020-2031
9.2 Latin America Immuno-Oncology Market Facts & Figures by Country (2020-2031)
9.3 Latin America Immuno-Oncology Revenue by Type (2020-2025)
9.4 Latin America Immuno-Oncology Revenue by Application (2020-2025)
10 Middle East and Africa
10.1 Latin America Immuno-Oncology Market Size YoY Growth 2020-2031
10.2 Middle East and Africa Immuno-Oncology Market Facts & Figures by Country (2020-2031)
10.3 Middle East and Africa Immuno-Oncology Revenue by Type (2020-2025)
10.4 Middle East and Africa Immuno-Oncology Revenue by Application (2020-2025)
11 Supply Chain and Sales Channel analysis
11.1 Immuno-Oncology Supply Chain Analysis
11.2 Immuno-Oncology Key Raw Materials and Upstream Suppliers
11.3 Immuno-Oncology Clients Analysis
11.4 Immuno-Oncology Sales Channel and Sales Model Analysis
11.4.1 Immuno-Oncology Distribution Channel Analysis: Indirect Sales VS Direct Sales
11.4.2 Immuno-Oncology Distribution Channel Analysis: Online Sales VS Offline Sales
11.4.3 Immuno-Oncology Distributors
12 Immuno-Oncology Market Dynamics
12.1 Immuno-Oncology Industry Trends
12.2 Immuno-Oncology Market Drivers
12.3 Immuno-Oncology Market Challenges
12.4 Immuno-Oncology Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
List of Tables
Table 1. Global Immuno-Oncology Market Size Growth Rate (CAGR) by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Immuno-Oncology Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Immuno-Oncology Market Size by Region (US$ Million): 2024 VS 2031
Table 4. Global Immuno-Oncology Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Immuno-Oncology Revenue Forecast by Region (2026-2031) & (US$ Million)
Table 6. Global Immuno-Oncology Revenue by Type (2020-2025) & (US$ Million)
Table 7. Global Immuno-Oncology Revenue Forecast by Type (2026-2031) & (US$ Million)
Table 8. Global Immuno-Oncology Revenue by Application (2020-2025) & (US$ Million)
Table 9. Global Immuno-Oncology Revenue Forecast by Application (2026-2031) & (US$ Million)
Table 10. Immuno-Oncology Revenue by Company (2020-2025) & (US$ Million)
Table 11. Immuno-Oncology Revenue Share by Company (2020-2025)
Table 12. Ranking of Global Top Immuno-Oncology Players by Revenue (US$ Million) in 2024
Table 13. Global Immuno-Oncology Companies Market Concentration Ratio (CR5 and HHI) & (2020-2025)
Table 14. Global Immuno-Oncology by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immuno-Oncology as of 2024)
Table 15. Global Immuno-Oncology Companies Headquarters
Table 16. Date of International Companies Enter into Immuno-Oncology Market
Table 17. Global Immuno-Oncology Companies Product & Service
Table 18. Global Immuno-Oncology Mergers & Acquisitions, Expansion Plans
Table 19. Bristol-Myers Squibb Corporation Information
Table 20. Bristol-Myers Squibb Description and Business Overview
Table 21. Bristol-Myers Squibb Immuno-Oncology Product
Table 22. Bristol-Myers Squibb Immuno-Oncology Revenue (US$ Million) and Gross Margin (2020-2025)
Table 23. Bristol-Myers Squibb Revenue Proportion of Immuno-Oncology by Product in 2024
Table 24. Bristol-Myers Squibb Revenue Proportion of Immuno-Oncology by Application in 2024
Table 25. Bristol-Myers Squibb Revenue Proportion of Immuno-Oncology by Geographic Area in 2024
Table 26. Bristol-Myers Squibb Recent Developments
Table 27. Merck & Co., Inc. Corporation Information
Table 28. Merck & Co., Inc. Description and Business Overview
Table 29. Merck & Co., Inc. Immuno-Oncology Product
Table 30. Merck & Co., Inc. Immuno-Oncology Revenue (US$ Million) and Gross Margin (2020-2025)
Table 31. Merck & Co., Inc. Revenue Proportion of Immuno-Oncology by Product in 2024
Table 32. Merck & Co., Inc. Revenue Proportion of Immuno-Oncology by Application in 2024
Table 33. Merck & Co., Inc. Revenue Proportion of Immuno-Oncology by Geographic Area in 2024
Table 34. Merck & Co., Inc. Recent Developments
Table 35. Roche AG Corporation Information
Table 36. Roche AG Description and Business Overview
Table 37. Roche AG Immuno-Oncology Product
Table 38. Roche AG Immuno-Oncology Revenue (US$ Million) and Gross Margin (2020-2025)
Table 39. Roche AG Revenue Proportion of Immuno-Oncology by Product in 2024
Table 40. Roche AG Revenue Proportion of Immuno-Oncology by Application in 2024
Table 41. Roche AG Revenue Proportion of Immuno-Oncology by Geographic Area in 2024
Table 42. Roche AG Recent Developments
Table 43. AstraZeneca, Plc Corporation Information
Table 44. AstraZeneca, Plc Description and Business Overview
Table 45. AstraZeneca, Plc Immuno-Oncology Product
Table 46. AstraZeneca, Plc Immuno-Oncology Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. AstraZeneca, Plc Revenue Proportion of Immuno-Oncology by Product in 2024
Table 48. AstraZeneca, Plc Revenue Proportion of Immuno-Oncology by Application in 2024
Table 49. AstraZeneca, Plc Revenue Proportion of Immuno-Oncology by Geographic Area in 2024
Table 50. AstraZeneca, Plc Recent Developments
Table 51. Sanofi S.A. Corporation Information
Table 52. Sanofi S.A. Description and Business Overview
Table 53. Sanofi S.A. Immuno-Oncology Product
Table 54. Sanofi S.A. Immuno-Oncology Revenue (US$ Million) and Gross Margin (2020-2025)
Table 55. Sanofi S.A. Revenue Proportion of Immuno-Oncology by Product in 2024
Table 56. Sanofi S.A. Revenue Proportion of Immuno-Oncology by Application in 2024
Table 57. Sanofi S.A. Revenue Proportion of Immuno-Oncology by Geographic Area in 2024
Table 58. Sanofi S.A. Recent Developments
Table 59. Dendreon Pharmaceuticals Corporation Information
Table 60. Dendreon Pharmaceuticals Description and Business Overview
Table 61. Dendreon Pharmaceuticals Immuno-Oncology Product
Table 62. Dendreon Pharmaceuticals Immuno-Oncology Revenue (US$ Million) and Gross Margin (2020-2025)
Table 63. Dendreon Pharmaceuticals Revenue Proportion of Immuno-Oncology by Product in 2024
Table 64. Dendreon Pharmaceuticals Revenue Proportion of Immuno-Oncology by Application in 2024
Table 65. Dendreon Pharmaceuticals Revenue Proportion of Immuno-Oncology by Geographic Area in 2024
Table 66. Dendreon Pharmaceuticals Recent Developments
Table 67. Novartis Corporation Information
Table 68. Novartis Description and Business Overview
Table 69. Novartis Immuno-Oncology Product
Table 70. Novartis Immuno-Oncology Revenue (US$ Million) and Gross Margin (2020-2025)
Table 71. Novartis Revenue Proportion of Immuno-Oncology by Product in 2024
Table 72. Novartis Revenue Proportion of Immuno-Oncology by Application in 2024
Table 73. Novartis Revenue Proportion of Immuno-Oncology by Geographic Area in 2024
Table 74. Novartis Recent Developments
Table 75. Gilead Sciences Inc. Corporation Information
Table 76. Gilead Sciences Inc. Description and Business Overview
Table 77. Gilead Sciences Inc. Immuno-Oncology Product
Table 78. Gilead Sciences Inc. Immuno-Oncology Revenue (US$ Million) and Gross Margin (2020-2025)
Table 79. Gilead Sciences Inc. Revenue Proportion of Immuno-Oncology by Product in 2024
Table 80. Gilead Sciences Inc. Revenue Proportion of Immuno-Oncology by Application in 2024
Table 81. Gilead Sciences Inc. Revenue Proportion of Immuno-Oncology by Geographic Area in 2024
Table 82. Gilead Sciences Inc. Recent Developments
Table 83. Merck KGaA Corporation Information
Table 84. Merck KGaA Description and Business Overview
Table 85. Merck KGaA Immuno-Oncology Product
Table 86. Merck KGaA Immuno-Oncology Revenue (US$ Million) and Gross Margin (2020-2025)
Table 87. Merck KGaA Revenue Proportion of Immuno-Oncology by Product in 2024
Table 88. Merck KGaA Revenue Proportion of Immuno-Oncology by Application in 2024
Table 89. Merck KGaA Revenue Proportion of Immuno-Oncology by Geographic Area in 2024
Table 90. Merck KGaA Recent Developments
Table 91. North America Immuno-Oncology Revenue by Country (2020-2025) & (US$ Million)
Table 92. North America Immuno-Oncology Revenue by Country (2026-2031) & (US$ Million)
Table 93. North America Immuno-Oncology Revenue by Type (2020-2025) & (US$ Million)
Table 94. North America Immuno-Oncology Revenue by Application (2020-2025) & (US$ Million)
Table 95. Asia-Pacific Immuno-Oncology Revenue by Region (2020-2025) & (US$ Million)
Table 96. Asia-Pacific Immuno-Oncology Revenue by Region (2026-2031) & (US$ Million)
Table 97. Asia-Pacific Immuno-Oncology Revenue by Type (2020-2025) & (US$ Million)
Table 98. Asia-Pacific Immuno-Oncology Revenue by Application (2020-2025) & (US$ Million)
Table 99. Europe Immuno-Oncology Revenue by Country (2020-2025) & (US$ Million)
Table 100. Europe Immuno-Oncology Revenue by Country (2026-2031) & (US$ Million)
Table 101. Europe Immuno-Oncology Revenue by Type (2020-2025) & (US$ Million)
Table 102. Europe Immuno-Oncology Revenue by Application (2020-2025) & (US$ Million)
Table 103. Latin America Immuno-Oncology Revenue by Country (2020-2025) & (US$ Million)
Table 104. Latin America Immuno-Oncology Revenue by Country (2026-2031) & (US$ Million)
Table 105. Latin America Immuno-Oncology Revenue by Type (2020-2025) & (US$ Million)
Table 106. Latin America Immuno-Oncology Revenue by Application (2020-2025) & (US$ Million)
Table 107. Middle East and Africa Immuno-Oncology Revenue by Country (2020-2025) & (US$ Million)
Table 108. Middle East and Africa Immuno-Oncology Revenue by Country (2026-2031) & (US$ Million)
Table 109. Middle East and Africa Immuno-Oncology Revenue by Type (2020-2025) & (US$ Million)
Table 110. Middle East and Africa Immuno-Oncology Revenue by Application (2020-2025) & (US$ Million)
Table 111. Immuno-Oncology Key Raw Materials, Industry Status and Trend
Table 112. Immuno-Oncology Key Raw Materials and Upstream Suppliers
Table 113. Immuno-Oncology Clients Status and Trend
Table 114. Immuno-Oncology Typical Clients
Table 115. Immuno-Oncology Distributors
Table 116. Immuno-Oncology Market Trends
Table 117. Immuno-Oncology Market Drivers
Table 118. Immuno-Oncology Market Challenges
Table 119. Immuno-Oncology Market Restraints
Table 120. Research Programs/Design for This Report
Table 121. Key Data Information from Secondary Sources
Table 122. Key Data Information from Primary Sources
List of Figures
Figure 1. Immuno-Oncology Product Picture
Figure 2. Global Immuno-Oncology Market Size by Type (US$ Million): 2020 VS 2024 VS 2031
Figure 3. Global Immuno-Oncology Revenue Market Share by Type in 2024 & 2031
Figure 4. Immune Checkpoint Inhibitors Product Picture
Figure 5. Cytokine-Based Immunotherapy Product Picture
Figure 6. Cancer Vaccines Product Picture
Figure 7. CAR-T Cell Therapy Product Picture
Figure 8. Others Product Picture
Figure 9. Global Immuno-Oncology Market Size by Application (US$ Million): 2020 VS 2024 VS 2031
Figure 10. Global Immuno-Oncology Revenue Market Share by Application in 2024 & 2031
Figure 11. Hospitals
Figure 12. Drugstores
Figure 13. Others
Figure 14. Immuno-Oncology Report Years Considered
Figure 15. Global Immuno-Oncology Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Immuno-Oncology Market Size (2020-2031) & (US$ Million)
Figure 17. Global Immuno-Oncology Market Size Market Share by Region: 2024 Versus 2031
Figure 18. Global Immuno-Oncology Revenue Market Share by Region (2020-2031)
Figure 19. Global Immuno-Oncology Revenue Market Share Forecast by Type (2020-2031)
Figure 20. Global Immuno-Oncology Revenue Market Share Forecast by Application (2020-2031)
Figure 21. Immune Checkpoint Inhibitors of Immuno-Oncology Revenue Market Share by Application, 2024 VS 2031
Figure 22. Cytokine-Based Immunotherapy of Immuno-Oncology Revenue Market Share by Application, 2024 VS 2031
Figure 23. Cancer Vaccines of Immuno-Oncology Revenue Market Share by Application, 2024 VS 2031
Figure 24. CAR-T Cell Therapy of Immuno-Oncology Revenue Market Share by Application, 2024 VS 2031
Figure 25. Others of Immuno-Oncology Revenue Market Share by Application, 2024 VS 2031
Figure 26. Immuno-Oncology Revenue Share by Company (2024)
Figure 27. Immuno-Oncology Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 28. Immune Checkpoint Inhibitors Revenue Proportion by Company in 2024
Figure 29. Cytokine-Based Immunotherapy Revenue Proportion by Company in 2024
Figure 30. Cancer Vaccines Revenue Proportion by Company in 2024
Figure 31. CAR-T Cell Therapy Revenue Proportion by Company in 2024
Figure 32. Others Revenue Proportion by Company in 2024
Figure 33. North America Immuno-Oncology Revenue 2020-2031 (US$ Million)
Figure 34. North America Immuno-Oncology Revenue Market Share by Type (2020-2025)
Figure 35. North America Immuno-Oncology Revenue Market Share by Application (2020-2025)
Figure 36. Asia-Pacific Immuno-Oncology Revenue 2020-2031 (US$ Million)
Figure 37. Asia-Pacific Immuno-Oncology Revenue Market Share by Region (2020-2031)
Figure 38. Asia-Pacific Immuno-Oncology Revenue Market Share by Type (2020-2025)
Figure 39. Asia-Pacific Immuno-Oncology Revenue Market Share by Application (2020-2025)
Figure 40. Europe Immuno-Oncology Revenue Growth Rate 2020-2031 (US$ Million)
Figure 41. Europe Immuno-Oncology Revenue Market Share by Country (2020-2031)
Figure 42. Europe Immuno-Oncology Revenue Market Share by Type (2020-2025)
Figure 43. Europe Immuno-Oncology Revenue Market Share by Application (2020-2025)
Figure 44. Latin America Immuno-Oncology Revenue Growth Rate 2020-2031 (US$ Million)
Figure 45. Latin America Immuno-Oncology Revenue Market Share by Country (2020-2031)
Figure 46. Latin America Immuno-Oncology Revenue Market Share by Type (2020-2025)
Figure 47. Latin America Immuno-Oncology Revenue Market Share by Application (2020-2025)
Figure 48. Middle East and Africa Immuno-Oncology Revenue Growth Rate 2020-2031 (US$ Million)
Figure 49. Middle East and Africa Immuno-Oncology Revenue Market Share by Country (2020-2031)
Figure 50. Middle East and Africa Immuno-Oncology Revenue Market Share by Type (2020-2025)
Figure 51. Middle East and Africa Immuno-Oncology Revenue Market Share by Application (2020-2025)
Figure 52. Immuno-Oncology Supply Chain (Upstream and Downstream Market)
Figure 53. Global Production Market Share of Immuno-Oncology Raw Materials by Region in 2024
Figure 54. Immuno-Oncology Distribution Channels
Figure 55. Global Immuno-Oncology Percentage 2020-2031: Indirect Sales VS Direct Sales
Figure 56. Global Immuno-Oncology Percentage 2020-2031: Online Sales VS Offline Sales
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
Table 1. Global Immuno-Oncology Market Size Growth Rate (CAGR) by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Immuno-Oncology Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Immuno-Oncology Market Size by Region (US$ Million): 2024 VS 2031
Table 4. Global Immuno-Oncology Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Immuno-Oncology Revenue Forecast by Region (2026-2031) & (US$ Million)
Table 6. Global Immuno-Oncology Revenue by Type (2020-2025) & (US$ Million)
Table 7. Global Immuno-Oncology Revenue Forecast by Type (2026-2031) & (US$ Million)
Table 8. Global Immuno-Oncology Revenue by Application (2020-2025) & (US$ Million)
Table 9. Global Immuno-Oncology Revenue Forecast by Application (2026-2031) & (US$ Million)
Table 10. Immuno-Oncology Revenue by Company (2020-2025) & (US$ Million)
Table 11. Immuno-Oncology Revenue Share by Company (2020-2025)
Table 12. Ranking of Global Top Immuno-Oncology Players by Revenue (US$ Million) in 2024
Table 13. Global Immuno-Oncology Companies Market Concentration Ratio (CR5 and HHI) & (2020-2025)
Table 14. Global Immuno-Oncology by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immuno-Oncology as of 2024)
Table 15. Global Immuno-Oncology Companies Headquarters
Table 16. Date of International Companies Enter into Immuno-Oncology Market
Table 17. Global Immuno-Oncology Companies Product & Service
Table 18. Global Immuno-Oncology Mergers & Acquisitions, Expansion Plans
Table 19. Bristol-Myers Squibb Corporation Information
Table 20. Bristol-Myers Squibb Description and Business Overview
Table 21. Bristol-Myers Squibb Immuno-Oncology Product
Table 22. Bristol-Myers Squibb Immuno-Oncology Revenue (US$ Million) and Gross Margin (2020-2025)
Table 23. Bristol-Myers Squibb Revenue Proportion of Immuno-Oncology by Product in 2024
Table 24. Bristol-Myers Squibb Revenue Proportion of Immuno-Oncology by Application in 2024
Table 25. Bristol-Myers Squibb Revenue Proportion of Immuno-Oncology by Geographic Area in 2024
Table 26. Bristol-Myers Squibb Recent Developments
Table 27. Merck & Co., Inc. Corporation Information
Table 28. Merck & Co., Inc. Description and Business Overview
Table 29. Merck & Co., Inc. Immuno-Oncology Product
Table 30. Merck & Co., Inc. Immuno-Oncology Revenue (US$ Million) and Gross Margin (2020-2025)
Table 31. Merck & Co., Inc. Revenue Proportion of Immuno-Oncology by Product in 2024
Table 32. Merck & Co., Inc. Revenue Proportion of Immuno-Oncology by Application in 2024
Table 33. Merck & Co., Inc. Revenue Proportion of Immuno-Oncology by Geographic Area in 2024
Table 34. Merck & Co., Inc. Recent Developments
Table 35. Roche AG Corporation Information
Table 36. Roche AG Description and Business Overview
Table 37. Roche AG Immuno-Oncology Product
Table 38. Roche AG Immuno-Oncology Revenue (US$ Million) and Gross Margin (2020-2025)
Table 39. Roche AG Revenue Proportion of Immuno-Oncology by Product in 2024
Table 40. Roche AG Revenue Proportion of Immuno-Oncology by Application in 2024
Table 41. Roche AG Revenue Proportion of Immuno-Oncology by Geographic Area in 2024
Table 42. Roche AG Recent Developments
Table 43. AstraZeneca, Plc Corporation Information
Table 44. AstraZeneca, Plc Description and Business Overview
Table 45. AstraZeneca, Plc Immuno-Oncology Product
Table 46. AstraZeneca, Plc Immuno-Oncology Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. AstraZeneca, Plc Revenue Proportion of Immuno-Oncology by Product in 2024
Table 48. AstraZeneca, Plc Revenue Proportion of Immuno-Oncology by Application in 2024
Table 49. AstraZeneca, Plc Revenue Proportion of Immuno-Oncology by Geographic Area in 2024
Table 50. AstraZeneca, Plc Recent Developments
Table 51. Sanofi S.A. Corporation Information
Table 52. Sanofi S.A. Description and Business Overview
Table 53. Sanofi S.A. Immuno-Oncology Product
Table 54. Sanofi S.A. Immuno-Oncology Revenue (US$ Million) and Gross Margin (2020-2025)
Table 55. Sanofi S.A. Revenue Proportion of Immuno-Oncology by Product in 2024
Table 56. Sanofi S.A. Revenue Proportion of Immuno-Oncology by Application in 2024
Table 57. Sanofi S.A. Revenue Proportion of Immuno-Oncology by Geographic Area in 2024
Table 58. Sanofi S.A. Recent Developments
Table 59. Dendreon Pharmaceuticals Corporation Information
Table 60. Dendreon Pharmaceuticals Description and Business Overview
Table 61. Dendreon Pharmaceuticals Immuno-Oncology Product
Table 62. Dendreon Pharmaceuticals Immuno-Oncology Revenue (US$ Million) and Gross Margin (2020-2025)
Table 63. Dendreon Pharmaceuticals Revenue Proportion of Immuno-Oncology by Product in 2024
Table 64. Dendreon Pharmaceuticals Revenue Proportion of Immuno-Oncology by Application in 2024
Table 65. Dendreon Pharmaceuticals Revenue Proportion of Immuno-Oncology by Geographic Area in 2024
Table 66. Dendreon Pharmaceuticals Recent Developments
Table 67. Novartis Corporation Information
Table 68. Novartis Description and Business Overview
Table 69. Novartis Immuno-Oncology Product
Table 70. Novartis Immuno-Oncology Revenue (US$ Million) and Gross Margin (2020-2025)
Table 71. Novartis Revenue Proportion of Immuno-Oncology by Product in 2024
Table 72. Novartis Revenue Proportion of Immuno-Oncology by Application in 2024
Table 73. Novartis Revenue Proportion of Immuno-Oncology by Geographic Area in 2024
Table 74. Novartis Recent Developments
Table 75. Gilead Sciences Inc. Corporation Information
Table 76. Gilead Sciences Inc. Description and Business Overview
Table 77. Gilead Sciences Inc. Immuno-Oncology Product
Table 78. Gilead Sciences Inc. Immuno-Oncology Revenue (US$ Million) and Gross Margin (2020-2025)
Table 79. Gilead Sciences Inc. Revenue Proportion of Immuno-Oncology by Product in 2024
Table 80. Gilead Sciences Inc. Revenue Proportion of Immuno-Oncology by Application in 2024
Table 81. Gilead Sciences Inc. Revenue Proportion of Immuno-Oncology by Geographic Area in 2024
Table 82. Gilead Sciences Inc. Recent Developments
Table 83. Merck KGaA Corporation Information
Table 84. Merck KGaA Description and Business Overview
Table 85. Merck KGaA Immuno-Oncology Product
Table 86. Merck KGaA Immuno-Oncology Revenue (US$ Million) and Gross Margin (2020-2025)
Table 87. Merck KGaA Revenue Proportion of Immuno-Oncology by Product in 2024
Table 88. Merck KGaA Revenue Proportion of Immuno-Oncology by Application in 2024
Table 89. Merck KGaA Revenue Proportion of Immuno-Oncology by Geographic Area in 2024
Table 90. Merck KGaA Recent Developments
Table 91. North America Immuno-Oncology Revenue by Country (2020-2025) & (US$ Million)
Table 92. North America Immuno-Oncology Revenue by Country (2026-2031) & (US$ Million)
Table 93. North America Immuno-Oncology Revenue by Type (2020-2025) & (US$ Million)
Table 94. North America Immuno-Oncology Revenue by Application (2020-2025) & (US$ Million)
Table 95. Asia-Pacific Immuno-Oncology Revenue by Region (2020-2025) & (US$ Million)
Table 96. Asia-Pacific Immuno-Oncology Revenue by Region (2026-2031) & (US$ Million)
Table 97. Asia-Pacific Immuno-Oncology Revenue by Type (2020-2025) & (US$ Million)
Table 98. Asia-Pacific Immuno-Oncology Revenue by Application (2020-2025) & (US$ Million)
Table 99. Europe Immuno-Oncology Revenue by Country (2020-2025) & (US$ Million)
Table 100. Europe Immuno-Oncology Revenue by Country (2026-2031) & (US$ Million)
Table 101. Europe Immuno-Oncology Revenue by Type (2020-2025) & (US$ Million)
Table 102. Europe Immuno-Oncology Revenue by Application (2020-2025) & (US$ Million)
Table 103. Latin America Immuno-Oncology Revenue by Country (2020-2025) & (US$ Million)
Table 104. Latin America Immuno-Oncology Revenue by Country (2026-2031) & (US$ Million)
Table 105. Latin America Immuno-Oncology Revenue by Type (2020-2025) & (US$ Million)
Table 106. Latin America Immuno-Oncology Revenue by Application (2020-2025) & (US$ Million)
Table 107. Middle East and Africa Immuno-Oncology Revenue by Country (2020-2025) & (US$ Million)
Table 108. Middle East and Africa Immuno-Oncology Revenue by Country (2026-2031) & (US$ Million)
Table 109. Middle East and Africa Immuno-Oncology Revenue by Type (2020-2025) & (US$ Million)
Table 110. Middle East and Africa Immuno-Oncology Revenue by Application (2020-2025) & (US$ Million)
Table 111. Immuno-Oncology Key Raw Materials, Industry Status and Trend
Table 112. Immuno-Oncology Key Raw Materials and Upstream Suppliers
Table 113. Immuno-Oncology Clients Status and Trend
Table 114. Immuno-Oncology Typical Clients
Table 115. Immuno-Oncology Distributors
Table 116. Immuno-Oncology Market Trends
Table 117. Immuno-Oncology Market Drivers
Table 118. Immuno-Oncology Market Challenges
Table 119. Immuno-Oncology Market Restraints
Table 120. Research Programs/Design for This Report
Table 121. Key Data Information from Secondary Sources
Table 122. Key Data Information from Primary Sources
List of Figures
Figure 1. Immuno-Oncology Product Picture
Figure 2. Global Immuno-Oncology Market Size by Type (US$ Million): 2020 VS 2024 VS 2031
Figure 3. Global Immuno-Oncology Revenue Market Share by Type in 2024 & 2031
Figure 4. Immune Checkpoint Inhibitors Product Picture
Figure 5. Cytokine-Based Immunotherapy Product Picture
Figure 6. Cancer Vaccines Product Picture
Figure 7. CAR-T Cell Therapy Product Picture
Figure 8. Others Product Picture
Figure 9. Global Immuno-Oncology Market Size by Application (US$ Million): 2020 VS 2024 VS 2031
Figure 10. Global Immuno-Oncology Revenue Market Share by Application in 2024 & 2031
Figure 11. Hospitals
Figure 12. Drugstores
Figure 13. Others
Figure 14. Immuno-Oncology Report Years Considered
Figure 15. Global Immuno-Oncology Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Immuno-Oncology Market Size (2020-2031) & (US$ Million)
Figure 17. Global Immuno-Oncology Market Size Market Share by Region: 2024 Versus 2031
Figure 18. Global Immuno-Oncology Revenue Market Share by Region (2020-2031)
Figure 19. Global Immuno-Oncology Revenue Market Share Forecast by Type (2020-2031)
Figure 20. Global Immuno-Oncology Revenue Market Share Forecast by Application (2020-2031)
Figure 21. Immune Checkpoint Inhibitors of Immuno-Oncology Revenue Market Share by Application, 2024 VS 2031
Figure 22. Cytokine-Based Immunotherapy of Immuno-Oncology Revenue Market Share by Application, 2024 VS 2031
Figure 23. Cancer Vaccines of Immuno-Oncology Revenue Market Share by Application, 2024 VS 2031
Figure 24. CAR-T Cell Therapy of Immuno-Oncology Revenue Market Share by Application, 2024 VS 2031
Figure 25. Others of Immuno-Oncology Revenue Market Share by Application, 2024 VS 2031
Figure 26. Immuno-Oncology Revenue Share by Company (2024)
Figure 27. Immuno-Oncology Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 28. Immune Checkpoint Inhibitors Revenue Proportion by Company in 2024
Figure 29. Cytokine-Based Immunotherapy Revenue Proportion by Company in 2024
Figure 30. Cancer Vaccines Revenue Proportion by Company in 2024
Figure 31. CAR-T Cell Therapy Revenue Proportion by Company in 2024
Figure 32. Others Revenue Proportion by Company in 2024
Figure 33. North America Immuno-Oncology Revenue 2020-2031 (US$ Million)
Figure 34. North America Immuno-Oncology Revenue Market Share by Type (2020-2025)
Figure 35. North America Immuno-Oncology Revenue Market Share by Application (2020-2025)
Figure 36. Asia-Pacific Immuno-Oncology Revenue 2020-2031 (US$ Million)
Figure 37. Asia-Pacific Immuno-Oncology Revenue Market Share by Region (2020-2031)
Figure 38. Asia-Pacific Immuno-Oncology Revenue Market Share by Type (2020-2025)
Figure 39. Asia-Pacific Immuno-Oncology Revenue Market Share by Application (2020-2025)
Figure 40. Europe Immuno-Oncology Revenue Growth Rate 2020-2031 (US$ Million)
Figure 41. Europe Immuno-Oncology Revenue Market Share by Country (2020-2031)
Figure 42. Europe Immuno-Oncology Revenue Market Share by Type (2020-2025)
Figure 43. Europe Immuno-Oncology Revenue Market Share by Application (2020-2025)
Figure 44. Latin America Immuno-Oncology Revenue Growth Rate 2020-2031 (US$ Million)
Figure 45. Latin America Immuno-Oncology Revenue Market Share by Country (2020-2031)
Figure 46. Latin America Immuno-Oncology Revenue Market Share by Type (2020-2025)
Figure 47. Latin America Immuno-Oncology Revenue Market Share by Application (2020-2025)
Figure 48. Middle East and Africa Immuno-Oncology Revenue Growth Rate 2020-2031 (US$ Million)
Figure 49. Middle East and Africa Immuno-Oncology Revenue Market Share by Country (2020-2031)
Figure 50. Middle East and Africa Immuno-Oncology Revenue Market Share by Type (2020-2025)
Figure 51. Middle East and Africa Immuno-Oncology Revenue Market Share by Application (2020-2025)
Figure 52. Immuno-Oncology Supply Chain (Upstream and Downstream Market)
Figure 53. Global Production Market Share of Immuno-Oncology Raw Materials by Region in 2024
Figure 54. Immuno-Oncology Distribution Channels
Figure 55. Global Immuno-Oncology Percentage 2020-2031: Indirect Sales VS Direct Sales
Figure 56. Global Immuno-Oncology Percentage 2020-2031: Online Sales VS Offline Sales
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Allergen Detection Market Research Report 2025
Jun 28, 25
Global Electronic Health Tracking System Market Research Report 2025
Jun 28, 25
Global Speciality Optical Fibers Market Research Report 2025
Jun 28, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232